Invasive candidiasis in critically ill adult patient;Candidiasis invasoras en el paciente crítico adulto

Revista Chilena de Infectologia

Volumn 28, Issue 1, 2011, Pages 41-49

  Tobar A , Eduardo ^a   Silva O , Francisco ^a   Olivares C , Roberto ^a   Gaete G , Pablo ^a   Luppi N , Mario ^a  

^a HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE   (Chile)

Author keywords

Critical illnesses; Echinocandins; Fungal infection; Mycoses Candida spp

Indexed keywords

EID: 79953289352     PISSN: 07161018     EISSN: None     Source Type: Journal    
DOI: 10.4067/s0716-10182011000100008     Document Type: Article

References (48)

1. Pappas P G, Kauffman C A, Andes D, Benjamin D K Jr, Calandra TF, Edwards J E Jr, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-35.
2. Almirante B, Rodríguez D, Park B J, Cuenca-Estrella M, Planes A M, Almela M, et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2005; 43: 1829-35.
3. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24, 179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-17.
4. Colombo A L, Nucci M, Park B J, Nouer S A, Arthington-Skaggs B, da Malta D A, et al. Epidcmiology of candidcmia in Brazil: a nationwide sentinel surveillance of candidcmia in eleven medical centers. J Clin Microbiol 2006; 44: 2816-23.
5. Nucci M, Queiroz-Telles F, Tobón A M, Restrepo A, Colombo A L, Epidcmiology of opportunistic fungal infections in Latin America. Clin Infect Dis 2010; 51 (5): 561-70.
6. Morgan J, Meltzer M I, Plikaytis B D, Sofair A N, Huie-While S, Wilcox S, et al. Excess mortality, hospital slay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol 2005; 26: 540-7.
7. Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer S, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37: 1172-7.
8. Rentz A M, Halpern M T, Bowden R, The impact of candidemia on length of hospital slay, outcome, and overall cost of illness. Clin Infect Dis 1998; 27: 781-8.
9. Falagas M E, Apostolou K E, Pappas V D, Attributable mortality of candidemia: a systematic review of matched cohort and case- control studies. Eur J Clin Microbiol Infect Dis 2006; 25: 419-25.
10. Silva V, Díaz M C, Febre N. Invasive fungal infections in Chile: a multicenter study of fungal prevalence and susceptibility during a 1-year period. Med Mycol 2004; 42: 333-9.
11. Horn D L, Neofytos D, Anaissie E J, Fishman J A, Steinbach W J, Olyaei A J, et al. Epidcmiology and outcomes of candidcmia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009; 48: 1695-703.
12. Marchetti O, Bille J, Fluckiger U, Eggimann P, Ruef C, Garbino J, et al. Epidemiology of candidemia in Swiss tertiary care hospitals: Secular trends, 1991 -2000. Clin Infect Dis 2004; 38: 311-20.
13. Tortorano A M, Biraghi E, Astolfi A, Ossi C, Tejada M, Farina C, and ITMUA Candidemia Study Group. European Confederation of Medical Mycology (ECMM). Prospective survey of candidemia: report from one Italian region. J Hosp Infect; 51: 297-304.
14. Bassetti M, Righi E, Costa A, Fasce R, Molinari M, Rosso R, et al. Epidemiological trends in nosocomial candidemia in intensive care. BMC Infectious Dis 2006; 6: 21-6.
15. Kung H C, Wang J L, Chang S C, Wang J T, Sun H Y, Hsueh P R, et al. Community-onset candidemia al a university hospital, 1995-2005. J Microbiol Immunol Infect 2007; 40: 355-63.
16. Shorr A F, Gupta V, Sun X, Johannes R S, Spalding J, Tabak Y P. Burden of early-onset candidemia: analysis of culture-positive bloodstream infections from a large U.S. database. Crit Care Med 2009; 37: 2519-26; quiz 2535.
17. Khatib R, Thirumoorthi M C, Riederer K M, Sturm L, Oney LA, Baran J Jr. Clustering of Candida infections in the neonatal intensive care unit: concurrent emergence of multiple Straits simulating intermittent outbreaks. Pediatr Infect Dis J 1998; 17 (2): 130-4.
18. Dizbay M, Kalkanci A, Sezer B E, Aktas F, Aydogan S, Fidan I, Kustimur S, Sugita T, Molecular investigation of a fungemia outbreak due to Candida parapsilosis in an intensive care unit. Braz J Infect Dis 2008; 12 (5): 395-9.
19. Pappas P G, Invasive candidiasis. Infect Dis Clin North Am 2006, 20 (3): 485-506.
20. Hardley S, Lee W W, Ruthazer R, Nasraway S A Jr. Candidemia as a cause of septic shock and multiple organic failure in noninmunocompromised patients. Crit Care Med 2002; 30 (8): 1808-14.
21. Guery B P, Arendrup M C, Auzinger G, Azoulay E, Borges Sá M, Johnson E M, et al. Management of invasive candidiasis and candidemia in adult non-neulropenic intensive care unit patients: Part I. Epidemiology and diagnosis. Intensive Care Med 2009; 35: 55-62.
22. O'Grady N P, Barie P S, Bartle J G, Bleck T, Carroll K, Kalil A C, et al. Guidelines for evaluation of new fever in critically ill adult patients: 2008 update from the American Collegue of Critical Care Medicine and the Infectious Disease Society of America. Crit Care Med 2008; 36 (4): 1330-49.
23. Voss A, Hollis R J, Pfaller M A, Wenzel R P, Doebbeling B N. Invesligalion of the sequence of colonization and candidcmia in nonneulropenic patients. J Clin Microbiol 1994; 32: 975-80.
24. Pillet D, Monod M, Suler P M, Frenk E, Auckenthaler R, Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994; 220: 751-8.
25. Leon C, Ruiz-Santana S, Saavedra P, Almirante B, Nolla-Salas J, Álvarez-Lerma F, et al. A bedside scoring system ("Candida score") for early antifungal treatment in nonneulropenic critically ill patients with Candida colonization. Crit Care Med 2006; 34: 730-7.
26. León C, Ruiz-Santana S, Saavedra P, Galvan B, Blanco A, Castro C, et al. Usefulness of the "Candida score" for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med 2009; 37: 1624-33.
27. Bennett J. Is real-time polymerase chain reactions ready for real use in detecting candidemia? Clin Infect Dis 2008; 46: 897-8.
28. McMullan R, Metwally L, Coyle P V, Hedderwick S, McCloskey B, O'Neill H J, et al. A prospective clinical trial of a realtime polymerase chain reaction assay for the diagnosis of candidemia in nonnculropcnic, critically ill adults. Clin Infect Dis 2008; 46: 890-6.
29. Kedzicrska A, Kochan P, Pietrzky A, Kedzicrska J. Current status of fungal wall components in the inmunodiagnostics of invasive fungal infections in humans: galactomannan, mannan and (1 -->3)-beta-D- glucan antigens. Hur J Clin Microbiol Infect Dis 2007; 26 (11): 755-66.
30. Lass-Flörl C, Perkhofer V, Mayr A. In vitro susceptibility testing in fungi: a global perspective on a variety of methods. Mycoses 2010; 53 (1): 1-11.
31. Garbino J, Lew D P, Romand J A, Hugonnet S, Auckenthaler R, Pittet D, Prevention of severe Candida infections in nonneulropenic, high-risk, critically ill patients: a randomized, double- blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med 2002; 28: 1708-17.
32. Piarroux R, Grenouillet F, Balvay P, Tran V, Blasco G, Millon L, et al. Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients. Crit Care Med 2004; 32: 2443-9.
33. Reboli A C, Rotstein C, Pappas P G, Chapman S W, Kelt D H, Kumar D, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356: 2472-82.
34. Gupta A K, Katz H I, Shear N H. Drug interactions with itraconazole, fluconazole, and terbinafine and their management. J Am Acad Dermatol 1999; 41 (2): 237-49.
35. Pittrow L, Penk A. Special pharmacokinetics of fluconazole in septic, obese and burn patients. Mycosis 1999; 42 Suppl 2: 87-90.
36. Washington C, Lance M, Davis S S, Toxicity of amphotericin B emulsion formulations. J Antimicrob Chemother 1993; 31: 806-8.
37. Mora-Duarte J, Bells R, Rotstein C, Colombo A L, Thompson-Moya L, Smielana J, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Iingl J Med 2002; 347: 2020-9.
38. Kline S, Larsen TA, Fieber L, Fishbach R, Greenwood M, Harris R, et al. Limited toxicity of prolonged therapy with high doses of amphotericin B lipid complex. Clin Infect Dis 1995; 21: 1154-8.
39. Heinemann V, Bosse D, Jehn U, Kähny B, Wachholz K, Debus A, et al. Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients. Antimicrb Agents Chemother 1997; 41 (6): 1275-80.
40. Kuse E R, Chetchotisakd P, da Cunha C A, Ruhnke M, Barrios C, Raghunadharao D, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007; 369: 1519-1527.
41. Sobel J D, Revankar S G. Hchinocandins: first-choice or first-line therapy for invasive candidiasis? N Engl J Med 2007; 356 (24): 2525-6.
42. Pappas P G, Rotstein C M, Bells R F, Nucci M, Talwar D, De Waele J J, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007; 45: 883-93.
43. Garey K W, Rege M, Pai M P, Mingo D E, Suda K J, Turpin R S, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006; 43: 25-31.
44. Patel G P, Simon D, Scheetz M, Crank C W, Lodise T, Patel N. The effect of lime to antifungal therapy on mortality in Candidemia associated septic shock. Am J Ther 2009; 16 (6): 508-11.
45. Guery B P, Arendrup M C, Auzinger G, Azoulay E, Borges Sá M, Johnson E M, et al. Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part II. Treatment. Intensive Care Med 2009; 35: 206-14.
46. Fraser V J, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan W C, Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 1992; 15: 414-21.
47. Morgan J. Global trends in candidemia: review of reports from 1995-2005. Curr Infect Dis Rep 2005; 7: 429-39.
48. Chow J K, Golan Y, Ruthazer R, Karehmer A W, Carmeli Y, Lichtenberg DA, et al. Risk factors for albicans and non-albicans candidemia in the intensive care unit. Crit Care Med 2008; 36: 1993-8.